KR101428113B1 - Ａ2ｂ 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법 - Google Patents

Ａ2ｂ 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법 Download PDF

Info

Publication number
KR101428113B1
KR101428113B1 KR1020087022707A KR20087022707A KR101428113B1 KR 101428113 B1 KR101428113 B1 KR 101428113B1 KR 1020087022707 A KR1020087022707 A KR 1020087022707A KR 20087022707 A KR20087022707 A KR 20087022707A KR 101428113 B1 KR101428113 B1 KR 101428113B1
Authority
KR
South Korea
Prior art keywords
formula
compound
methyl
dione
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087022707A
Other languages
English (en)
Korean (ko)
Other versions
KR20080107416A (ko
Inventor
디완 쩡
훙옌 중
루이즈 벨라디넬리
Original Assignee
길리애드 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 길리애드 사이언시즈, 인코포레이티드 filed Critical 길리애드 사이언시즈, 인코포레이티드
Publication of KR20080107416A publication Critical patent/KR20080107416A/ko
Application granted granted Critical
Publication of KR101428113B1 publication Critical patent/KR101428113B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087022707A 2006-03-17 2007-03-16 Ａ2ｂ 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법 Active KR101428113B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78357506P 2006-03-17 2006-03-17
US60/783,575 2006-03-17
PCT/US2007/064182 WO2007109547A2 (en) 2006-03-17 2007-03-16 Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
KR20080107416A KR20080107416A (ko) 2008-12-10
KR101428113B1 true KR101428113B1 (ko) 2014-08-07

Family

ID=38514256

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087022707A Active KR101428113B1 (ko) 2006-03-17 2007-03-16 Ａ2ｂ 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법

Country Status (14)

Country Link
US (4) US7795268B2 (enExample)
EP (1) EP1996201A2 (enExample)
JP (2) JP5250848B2 (enExample)
KR (1) KR101428113B1 (enExample)
CN (1) CN101405003B (enExample)
AU (1) AU2007227021B2 (enExample)
CA (2) CA2849661A1 (enExample)
IL (1) IL194158A0 (enExample)
MX (1) MX2008011828A (enExample)
NO (1) NO20083968L (enExample)
NZ (1) NZ571324A (enExample)
RU (1) RU2457842C2 (enExample)
WO (1) WO2007109547A2 (enExample)
ZA (1) ZA200807894B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018080127A1 (ko) * 2016-10-31 2018-05-03 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
EP1658291B1 (en) * 2003-08-25 2013-10-02 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
US20060159627A1 (en) 2004-10-15 2006-07-20 Dewan Zeng Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006091898A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyrazolyl substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
JP5044823B2 (ja) * 2005-06-16 2012-10-10 ギリアード サイエンシーズ， インコーポレイテッド Ａ２ｂアデノシンレセプターアンタゴニストのプロドラッグ
MX2008011828A (es) 2006-03-17 2008-09-29 Cv Therapeutics Inc Metodo para la prevencion y el tratamiento de enfermedad hepatica utilizando antagonistas del receptor de adenosina a2b.
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
ES2361886T3 (es) * 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
WO2009055021A1 (en) * 2007-10-26 2009-04-30 New York University School Of Medicine Methods and compositions for treating hepatic diseases
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
EP2616470B1 (en) 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
US20140142113A1 (en) * 2012-11-09 2014-05-22 Michael W. Burnet Method of treating inflammatory diseases using adenosine 2b receptor antagonists
WO2016057454A1 (en) 2014-10-06 2016-04-14 The Johns Hopkins University Targeting liver nuclear receptors as a treatment for wilson disease
KR101666605B1 (ko) 2015-02-13 2016-10-18 한국과학기술원 TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
WO2016129760A1 (ko) * 2015-02-13 2016-08-18 한국과학기술원 Tnp(n2-(m-trifluorobenzyl), n6-(p-nitrobenzyl)purine)를 유효성분으로 함유하는 아세트아미노펜 유래 간 독성 예방 및 치료용 조성물
EP3368064B1 (en) 2015-10-29 2021-05-19 CLS Therapeutics Limited Use of dnase to improve safety and efficacy of anti-cancer chemotherapy
WO2017139455A1 (en) 2016-02-10 2017-08-17 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
ES2951809T3 (es) * 2017-05-17 2023-10-25 Arcus Biosciences Inc Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer
EP3675856A4 (en) 2017-08-31 2021-04-14 Corvus Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR MODULATING THE A2B ADENOSINE RECEPTOR AND A2A ADENOSINE RECEPTOR
EP3762386B1 (en) * 2018-03-05 2024-01-24 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
US12064433B2 (en) 2018-07-27 2024-08-20 Arcus Biosciences, Inc. Pyridone A2R antagonists
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139428A1 (en) * 2001-11-09 2003-07-24 Rao Kalla A2B adenosine receptor antagonists
WO2003101455A2 (en) * 2002-05-30 2003-12-11 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2005070926A1 (en) * 2004-01-21 2005-08-04 Novartis Ag Thiazole derivatives as a2b antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
ES2208063B1 (es) * 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
WO2004086052A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
JP5044823B2 (ja) * 2005-06-16 2012-10-10 ギリアード サイエンシーズ， インコーポレイテッド Ａ２ｂアデノシンレセプターアンタゴニストのプロドラッグ
MX2008011828A (es) * 2006-03-17 2008-09-29 Cv Therapeutics Inc Metodo para la prevencion y el tratamiento de enfermedad hepatica utilizando antagonistas del receptor de adenosina a2b.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139428A1 (en) * 2001-11-09 2003-07-24 Rao Kalla A2B adenosine receptor antagonists
WO2003101455A2 (en) * 2002-05-30 2003-12-11 King Pharmaceuticals Research & Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2005070926A1 (en) * 2004-01-21 2005-08-04 Novartis Ag Thiazole derivatives as a2b antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Drug Development Research, Vol. 56, No. 4, p. 557, 2002. *
Drug Development Research, Vol. 56, No. 4, p. 557, 2002.*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018080127A1 (ko) * 2016-10-31 2018-05-03 퓨쳐메디신 주식회사 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물
US11266650B2 (en) 2016-10-31 2022-03-08 Future Medicine Co., Ltd. Pharmaceutical composition for preventing and treating nonalcoholic steatohepatitis, hepatic fibrosis, and liver cirrhosis, comprising adenosine derivatives

Also Published As

Publication number Publication date
US20120220608A1 (en) 2012-08-30
US8188099B2 (en) 2012-05-29
US7795268B2 (en) 2010-09-14
RU2008137279A (ru) 2010-03-27
CN101405003B (zh) 2011-05-11
CA2646333C (en) 2014-06-17
US20070219221A1 (en) 2007-09-20
NO20083968L (no) 2008-12-15
WO2007109547A3 (en) 2007-11-29
AU2007227021B2 (en) 2012-12-20
CA2849661A1 (en) 2007-09-27
JP2013049719A (ja) 2013-03-14
CA2646333A1 (en) 2007-09-27
RU2457842C2 (ru) 2012-08-10
US20140243358A1 (en) 2014-08-28
US8609671B2 (en) 2013-12-17
US20110184002A1 (en) 2011-07-28
KR20080107416A (ko) 2008-12-10
IL194158A0 (en) 2009-08-03
EP1996201A2 (en) 2008-12-03
CN101405003A (zh) 2009-04-08
JP2009530413A (ja) 2009-08-27
ZA200807894B (en) 2009-05-27
AU2007227021A1 (en) 2007-09-27
JP5250848B2 (ja) 2013-07-31
NZ571324A (en) 2011-07-29
WO2007109547A2 (en) 2007-09-27
MX2008011828A (es) 2008-09-29

Similar Documents

Publication Publication Date Title
KR101428113B1 (ko) Ａ2ｂ 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법
US8466129B2 (en) Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
KR101140186B1 (ko) Ａ2ｂ 아데노신 수용체 안타고니스트
US20120003329A1 (en) Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
AU2012261721A1 (en) Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
HK1156213A (en) Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080917

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120314

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130904

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20140401

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140501

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140801

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140801

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170724

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170724

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180726

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180726

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190724

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190724

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200630

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210629

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240619

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20250616

Start annual number: 12

End annual number: 12